TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics, Inc. (TRVI) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | D (1.5) | C (2.2) | C (2.2) | C+ (2.6) | C (2.2) |
| 2026-11-08 | C+ (2.5) | D (1.4) | C (2.2) | C (2.4) | C+ (2.6) | C (2.2) |
| 2026-11-01 | C+ (2.5) | D (1.4) | C (2.3) | C+ (2.6) | C+ (2.7) | C (2.3) |
| 2026-10-25 | C+ (2.5) | D (1.4) | C (2.3) | C (2.4) | C+ (2.6) | C (2.2) |
| 2026-10-18 | C+ (2.5) | D (1.4) | C (2.3) | C (2.4) | C+ (2.6) | C (2.2) |